Highlights from 2024 R.I. Best of ASCO by Wafik S. El-Deiry

Great things happened in Rhode Island on October 5th with a fantastic Best of ASCO event. The Best of ASCO was organized by Dr. Howard Safran as it has been for the last 4 years, with help from Stephanie Graffand, John Reagan.

Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, shared his insights on social media.

The Rhode Island Oncology Society in its role as an ASCO State Affiliate

“Excited about the impact of advocacy work in Rhode Island and looking forward to seeing much more in the future with the Rhode Island Oncology Society in its role as an ASCO State Affiliate. The Legorreta Cancer Center has been active in advocacy and policy work for several years at the State and Federal levels to make life better for Rhode Islanders. There is a heavy burden from cancer in the state across cancer types.”

He shared his post adding:

“I am reminded of the first time I went to advocate for NIH funding in 2006. I’ll share this editorial I wrote about the experience so that more of my colleagues step up and become more active for change. Many issues have not changed in nearly 20 years but I do believe that some day the government will listen and more highly prioritize research funding in the US. Lobbying congress to make cancer funding a priority: What scientists can do.”

Palliative care at the 2024 RI Best of ASCO conference

“Dr. Katherine Faricy-Anderson speaks about medicinal cannabis in symptom management and telehealth in palliative care at the 2024 RI Best of ASCO conference in Providence.”

The AdAPT-001 trial with Oncologic adenovirus expressing a TGFbeta trap

“Dr. Cara Mathews discusses the AdAPT-001 trial with Oncologic adenovirus expressing a TGFbeta trap at the 2024 RI Best of ASCO conference in Providence.

She showed some impressive results from the AdAPT-001 trial with checkpoint inhibitor Nivolumab or Pembrolizumab after progression on prior immunotherapy and with low TMB.”

Session on hematologic malignancies by Adam Olszewski and John Reagan

“Session on hematologic malignancies at 2024 R.I. Best of ASCO conference with presentations by Adam Olszewski and John Reagan.

Dr. Adam Olszewski discusses Epcoritamab in relapsed or refractory follicular lymphoma, current bi-specific antibodies for lymphoma and EPCORE. He discussed a case of a patient treated with Epcoritamab and BrUOG 401.

Dr. John Reagan describes CML monitoring and the ASC4FIRST phase III trial of Asciminib in newly diagnosed CML at the 2024 RI Best of ASCO conference in Providence.

Dr. Reagan also discussed a multi-site randomized collaborative palliative care and oncology care model for patients with acute AML and MDS receiving non-intensive therapy.”

Challenges in GI cancer and in particular pancreatic cancer

“Dr. Alex Raufi discusses challenges in GI cancer and in particular pancreatic cancer with dismal 5-year survival outcomes in 2024. He discusses two trials from the ASCO24 meeting that are non-practice changing. 2024 RI Best of ASCO meeting in Providence.”

The ESOPEC trial of perioperative FLOT vs neoadjuvant CROSS chemoradiotherapy

“Dr. Khaldoun Almhanna discusses the ESOPEC trial of perioperative FLOT vs neoadjuvant CROSS chemoradiotherapy for resectable esophageal adenocarcinoma at the 2024 RI Best of ASCO conference in Providence.”

Dr. Rimini Breakstone discusses progress from 3 trials

“Dr. Rimini Breakstone discusses progress from 3 trials in CRC including Dynamic, Checkmate 8HW, and TRANSMET at the 2024 RI Best of ASCO conference in Providence.”

Progress in melanoma therapeutics

“Dr. Matt Hadfield spoke about progress in melanoma therapeutics at the 2024 R.I. Best of ASCO conference in Providence, RI. COMBI-AD double-blind phase III study of randomization of adjuvant dabrafenib plus trametinib vs placebo in stage 3 BRAF-mutated melanoma.”

For more posts about 2024 R.I. Best of ASCO conference visit OncoDaily.com.